Celgene Corp (NASDAQ:CELG) Quarterly Sentiment Change Reported at 0.83

May 17, 2018 - By Dominique Gillenwater

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Positions for Celgene Corp (NASDAQ:CELG)

“Big money sentiment for Celgene Corp (NASDAQ:CELG) in 2017 Q4 decreased to 0.83, according to SEC.gov filings. So its down -0.34, from 2017Q3’s 1.17. 529 investment managers started new and increased positions, while 634 reduced and sold their equity positions in Celgene Corp so the sentiment dropped. Funds own 561.38 million shares, down from 603.99 million shares in 2017Q3. Funds holding Celgene Corp in top 10 changed to 38 from 119 for a decrease of 81. 156 Investors Sold All; 478 Reduced Holdings; 411 increased stakes while 118 investment managers bought stakes.

Largest Celgene Corp Shareholders

Birchview Capital Lp owns 744,051 shares in Celgene Corp as of 2017 Q4. Celgene Corp’s shareholder Oaktop Capital Management Ii L.P. owns 2.11 million shares as of 2017 Q4. Furthermore, Selkirk Management Llc reported 260,000 shares in Celgene Corp equivalent to 14.49% of its stocks portfolio. Bb Biotech Ag revealed 3.42 million shares position in Celgene Corp. The United Kingdom-based fund Edinburgh Partners Ltd looks positive on Celgene Corp, owning 315,906 shares.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The company has $59.09 billion market cap. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.The P/E ratio is 22.35. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

CELG is reaching $81.36 during the last trading session, after decreased 0.76%.Celgene Corporation has volume of 6.04 million shares. Since May 17, 2017 CELG has declined 31.28% and is downtrending. CELG underperformed the S&P 500 by 42.83%.

On July, 26 is anticipated Celgene Corporation (NASDAQ:CELG)’s earnings report, as reported by RTT. Analysts expect change of 11.31 % or $0.19 from previous year’s $1.68 earnings per share compared to current’s $1.87 earnings per share. If $1.87 is reported, CELG’s profit will reach $1.36B for 10.88 P/E. Last quarter $1.61 earnings per share was reported. Analysts sees 16.15 % EPS growth this quarter.

Mariner Wealth accumulated 44,678 shs. Amalgamated Natl Bank holds 102,626 shs or 0.29% of its capital. Hartford Investment Mngmt Company accumulated 0.33% or 170,139 shs. 75,507 are held by Braun Stacey Assocs Inc. New York-based First Long Island Ltd Llc has invested 1.8% in Celgene Corporation (NASDAQ:CELG). Warren Averett Asset Ltd Com stated it has 6,148 shs. Kcm Invest Advsrs Ltd Liability Co accumulated 3,684 shs. Cadence Natl Bank Na has 6,651 shs. Sg Americas Securities Llc invested in 0.08% or 79,501 shs. 9,026 were reported by Lmr Prtnrs Llp. Peapack Gladstone Financial Corporation has 81,857 shs for 0.46% of their capital. Busey holds 57,078 shs. Comerica Natl Bank accumulated 238,206 shs. Rhenman & Partners Asset Mgmt Ab reported 161,412 shs. 11,666 were accumulated by Fund Mngmt.

Celgene Corporation had 3 selling transactions and 1 insider purchase since February 8, 2018. This’s net activity of $3.58 million. $299,594 worth of stock was bought by Alles Mark J on Thursday, February 8. MARIO ERNEST sold 13,370 shs worth $1.26 million. $1.77M worth of stock was sold by KAPLAN GILLA on Thursday, February 15.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 20 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 13, “Sell” are 0, while 7 are “Hold”. 65% are bullish. With $152.0 highest and $90 lowest PT Celgene has $122 average PT or 49.95% above the current ($81.36) price. 35 are the (NASDAQ:CELG)’s analyst reports since December 8, 2017 according to StockzIntelligence Inc. On Wednesday, February 28 William Blair maintained Celgene Corporation (NASDAQ:CELG) with “Buy” rating. On Friday, April 13 the firm earned “Equal-Weight” rating by Morgan Stanley. On Wednesday, December 13 the rating was maintained by Leerink Swann with “Buy”. In Wednesday, February 28 report Stifel Nicolaus maintained it with “Buy” rating and $128 target. In Tuesday, February 13 report Barclays Capital upgraded the stock to “Buy” rating. On Thursday, January 25 the firm earned “Hold” rating by Piper Jaffray. In Monday, May 7 report Leerink Swann maintained the stock with “Buy” rating. On Monday, January 8 the rating was maintained by Stifel Nicolaus with “Buy”. On Tuesday, January 23 RBC Capital Markets maintained Celgene Corporation (NASDAQ:CELG) with “Buy” rating. In Thursday, January 18 report Piper Jaffray maintained it with “Hold” rating and $104.0 target.

For more Celgene Corporation (NASDAQ:CELG) news released recently go to: Fool.com, Nasdaq.com, Seekingalpha.com, Prnewswire.com or Streetinsider.com. The titles are as follows: “Celgene Starts the Year With a Bang” released on May 14, 2018, “Nohla Therapeutics Announces Closing of $45 Million Series B Financing” on May 15, 2018, “Generic Revlimid Could Sink Celgene” with a publish date: May 16, 2018, “Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead …” and the last “Celgene (CELG) to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at ASCO” with publication date: May 16, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: